Antibodies capable of binding to the human c-Met receptor and/or capable of inhibiting the tyrosine kinase activity of said receptor, with an improved antagonistic activity, the antibodies comprising a modified hinge region. A composition comprising one or more of such antibodies antagonist to c-Met and its use as a medicament for treating cancer.